Abstract: Embodiments of the disclosure provide a method for operating a combined cycle power plant (CCPP). The method may include creating a variant control profile for the CCPP for a power plant model of the CCPP. The method may include modifying the variant control profile in response to the variant control profile not reducing the fuel consumption or meeting the quality threshold. The method may also include adjusting the CCPP to use the variant control profile in response to the variant control profile reducing the fuel consumption and meeting the quality threshold. Using the variant control profile adjusts a turbine section inlet temperature schedule or an exhaust temperature schedule for the CCPP.

Abstract: An occlusion catheter system includes an inflation catheter member and an occlusion balloon. The proximal and distal balloon ends are connected to the inflation catheter between the proximal and distal catheter ends. A distal pressure sensor is attached to the inflation catheter member between the proximal balloon end and the atraumatic tip. An inflatable spine is connected to the inflation catheter. The proximal spine end is connected to the inflation catheter near the proximal balloon end and the distal spine end is connected to the inflation catheter near the distal balloon end. The occlusion balloon and the inflatable spine are configured to define blood flow channels with the internal surface and the external balloon surface when the occlusion catheter system is at least partially positioned in the vessel and the occlusion balloon and the inflatable spine are in a partially inflated configuration.

Abstract: Disclosed here are methods for treating a condition (e.g., cancer) with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for the use of effective combinations of proteins encoded by hot-spot mutations and/or tumor-associated mRNA splice variants to optimize the targeting of a patient's condition (e.g., cancer) with immunotherapies.

Abstract: A computer-implemented method for the identification of clinically relevant structural variants in a subject with AML or MDS from whole genome sequencing data is disclosed that includes providing a whole-genome sequencing dataset, performing a structural variant analysis on the whole-genome sequencing dataset and producing a report that includes clinically relevant CNAs, SVs, and gene-level variants identified by the structural variant analysis.

Abstract: An occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is connected to the proximal hub and has an inflation lumen. A stiffener member defines a longitudinal axis. The proximal end of the stiffener member is connected to the proximal hub. The stiffener member extends through a portion of the inflation lumen. An occlusion balloon has a proximal balloon end and a distal balloon end. A distal catheter member is positioned substantially on the longitudinal axis and is connected to the distal end of the stiffener member. An atraumatic tip is positioned on a distal end of the distal catheter member. The atraumatic tip has a substantially circular profile in a relaxed configuration. A pressure sensor is connected to the occlusion catheter system distally relative to the occlusion balloon and is connected to a processor by electrical wiring.

Abstract: A wireless device is configured to receive scheduling information at a predetermined time interval from a wireless node. The scheduling information includes a plurality of reception definitions. Each reception definition indicates a reception start time, a reception duration, and assigned frequency information. Each reception definition is derived from a wireless device identification associated with the reception definition. The wireless device is configured to receive data associated with at least one of the reception definitions.

Abstract: Systems and methods for installing and removing a downhole electric tool in a well, independent of an upper completion in the well. A connector on the interior of a tubular structure (e.g., production tubing or casing) serves as an electrical socket for the tool. This connector is coupled to electrical cables which run from the connector to the surface. The tool, which is raised and lowered on a wireline, slick line or coiled tubing, is plugged into this connector so the tool can be pulled from the socket using the wireline/slick line/coiled tubing and removed from the well without having to remove the tubular structure or other parts of the completion. A replacement tool can then be lowered into the tubular structure and, when the tool lands on the connector, it engages the connector and couples the tool through the cabling to the surface equipment.

Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

Abstract: An occlusion catheter system includes a proximal hub having an inflation connection port and an inflation pathway. An inflation catheter member is connected to the proximal hub and has an inflation lumen. A stiffener member defines a longitudinal axis. The proximal end of the stiffener member is connected to the proximal hub. The stiffener member extends through a portion of the inflation lumen. An occlusion balloon has a proximal balloon end and a distal balloon end. A distal catheter member is positioned substantially on the longitudinal axis and is connected to the distal end of the stiffener member. An atraumatic tip is positioned on a distal end of the distal catheter member. The atraumatic tip has a substantially circular profile in a relaxed configuration. A pressure sensor is connected to the occlusion catheter system distally relative to the occlusion balloon and is connected to a processor by electrical wiring.

Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.

Abstract: An occlusion catheter system includes an inflation catheter member and an occlusion balloon. The proximal and distal balloon ends are connected to the inflation catheter between the proximal and distal catheter ends. A distal pressure sensor is attached to the inflation catheter member between the proximal balloon end and the atraumatic tip. An inflatable spine is connected to the inflation catheter. The proximal spine end is connected to the inflation catheter near the proximal balloon end and the distal spine end is connected to the inflation catheter near the distal balloon end. The occlusion balloon and the inflatable spine are configured to define blood flow channels with the internal surface and the external balloon surface when the occlusion catheter system is at least partially positioned in the vessel and the occlusion balloon and the inflatable spine are in a partially inflated configuration.

Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating cells, including for example T cells and T cells that express chimeric antigen receptors, using an inducible chimeric polypeptide including CD40, MyD88, or CD40 and MyD88 polypeptides. The technology further relates in part to therapeutic methods for inducing an immune response and treating tumors in a patient.

Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.

Abstract: Systems, methods, and apparatuses are described for determining compliance with a plurality of restrictions associated with one or more devices in an organization. First text indicating restrictions may be received, and second text indicating a current configuration of one or more devices may be received. Both sets of text may be processed by, e.g., removing a portion of the text based on a predetermined list of terms and simplifying the text using a lemmatization algorithm. A first vector and second vector may be generated based on the processed sets of text, and each vector may be weighted based on an inverse frequency of words in their respective text. Each vector may be normalized based on semantic analysis. The two vectors may be compared. Based on the comparison, third text corresponding to a portion of the second vector may be generated and transmitted to a third computing device.

Abstract: Embodiments of the disclosure provide a method for operating a combined cycle power plant (CCPP). The method may include creating a variant control profile for the CCPP for a power plant model of the CCPP. The method may include modifying the variant control profile in response to the variant control profile not reducing the fuel consumption or meeting the quality threshold. The method may also include adjusting the CCPP to use the variant control profile in response to the variant control profile reducing the fuel consumption and meeting the quality threshold. Using the variant control profile adjusts a turbine section inlet temperature schedule or an exhaust temperature schedule for the CCPP.

Abstract: Embodiments of the disclosure provide a method for operating a combined cycle power plant (CCPP). The method may include generating a power plant model for operating the CCPP, determining whether at least two gas turbines in the power plant model generate a power output, and modeling a fuel consumption of the CCPP for a baseline split ratio between the at least two gas turbines. The method may also include determining whether the variant split ratio meets a quality threshold for the CCPP, and adjusting the CCPP to use the variant split ratio in response to the variant split ratio meeting the quality threshold.

Abstract: An epilamization agent containing at least one compound including at least hydrophobic and oleophobic moieties arranged to impart epilame properties to the compound, and at least one hydrophilic moiety arranged to make the compound soluble in aqueous medium, the hydrophilic moiety being linked to the compound by at least one cleavable group. A method for coating a substrate with epilame, including: preparing an aqueous epilamization bath by solubilising such an epilamization agent, placing the substrate in contact with the epilamization agent in the epilamization bath, separating the hydrophilic moiety from the epilamization agent by cleavage, rinsing the substrate to eliminate the hydrophilic residues from the hydrophilic moiety and drying.

Abstract: The present invention provides a patient inhalation/exhalation device such as a spirometer, respiratory inhaler or spacer, the device comprising: at least one aperture for inlet or outlet of air into/from the device; a mouthpiece for communication with the mouth of the patient; and a body defining an air flow path extending between the aperture and the mouthpiece along which air is drawn to the mouthpiece by inhalation by the patient or air is forced towards the aperture by exhalation by the patient. The body comprises an air flow rate indicator operable to generate a sound signal to indicate when the air flow rate along the air flow path is at or above a predetermined minimum level. In another aspect, the present invention provides a device for indicating a desired fluid flow rate along a fluid flow path through a respiratory inhaler.

Abstract: An adapter for fitting to a drug delivery device, the adapter including: an outlet for communication with the mouth of a patient; an air flow path through the adapter along which air is drawn to the outlet by inhalation by the patient; an inlet adapted for connection to a mouthpiece of the drug delivery device; and an air flow rate indicator operable to indicate when the air flow rate along the air flow path is at or above a predetermined minimum level suitable for delivery of the drug to the patient. A drug delivery device having, in its body, an air flow rate indicator operable to indicate when the air flow rate along the air flow path is at or above a predetermined minimum level suitable for delivery of the drug to the patient.

Abstract: An anchoring device for use in retaining a railway rail fastening clip having first and second leg portions and a rail-bearing portion therebetween. The anchoring device includes a base member, an opening in the base member configured to receive a fastening component for fastening the anchoring device to an underlying foundation, and first and second clip-retaining sides extending from said base member with the first clip-retaining side being spaced apart from the second clip-retaining side so as to define a space therebetween for receiving the rail-bearing portion of the clip. Each clip-retaining side comprising upper and lower clip contact walls defining a passageway for receiving one of the leg portions, wherein the leg portions contact the clip contact walls of the respective clip-retaining sides as the clip moves from a wedged position towards an engaged position where the rail-bearing portion of the clip bears on the rail.